Failure of adefovir 20 mg to improve suboptimal response in lamivudine-resistant hepatitis B patients treated with adefovir 10 mg and lamivudine

[Guest guest]

J Viral Hepat. 2008 Dec;15(12):922-4.

Failure of adefovir 20 mg to improve suboptimal response in lamivudine-resistant

hepatitis B patients treated with adefovir 10 mg and lamivudine.

Viganò M, Lampertico P, Facchetti F, Lunghi G, Colombo M.

" A. M. and A. Migliavacca " Center for Liver Disease, 1 Division of

Gastroenterology, Department of Medicine, Fondazione IRCCS Ospedale Maggiore

Policlinico, Mangiagalli e Regina Elena, University of Milan, Milan, Italy.

Nine patients with lamivudine-resistant chronic hepatitis B infection who had

been treated with adefovir 10 mg/day and had had a suboptimal response but did

not have genotypic resistance to adefovir were treated with high-dose adefovir

(20 mg/day). The response to the increased dose of adefovir was compared with

the response in 15 patients with a suboptimal response who did not receive an

increase in the dose of adefovir. The increase in the dose of adefovir did not

lead to a significant reduction in hepatitis B DNA when compared with patients

maintained on the standard dose. These data suggest that increasing the dose of

adefovir in patients with a suboptimal response does not lead to an improved

response.

PMID: 19087228 [PubMed - in process]